Europe approves Roche’s Tecentriq liver cancer combination
pharmaphorum
NOVEMBER 4, 2020
Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination, occurring in 2% or more of patients, were bleeding in the gastrointestinal tract and fever.
Let's personalize your content